Lightbeam Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Population health management and care coordination platform helping health systems and payers close care gaps and manage high-risk patients. Dallas TX.
About
Lightbeam Health is a population health management company that helps healthcare organizations identify, stratify, and engage high-risk patients to improve outcomes and reduce costs in value-based care arrangements. Headquartered in Dallas, Texas, Lightbeam serves health systems, ACOs, and health plans with a platform that aggregates clinical and claims data, applies predictive risk models, and delivers actionable patient lists to care management teams. The company has a strong presence in the ambulatory care market and among organizations pursuing Medicare Shared Savings Program and Medicare Advantage contracts.\n\nLightbeam's platform includes a comprehensive care management workflow tool that allows care coordinators to document interventions, manage care plans, and track outcomes across attributed patient populations. The system integrates with major EHR platforms to deliver real-time clinical context alongside population-level analytics, enabling care managers to move from insight to action without leaving their primary workflow environment. Lightbeam also supports quality measure tracking for HEDIS, CMS Stars, and commercial quality programs, giving organizations a single platform for both care management operations and performance reporting.\n\nThe company has grown through a combination of organic expansion and strategic partnerships with health IT ecosystem players. Lightbeam competes with vendors like Arcadia, Innovaccer, and Zeomega in the population health space, differentiating on depth of care management functionality and configurability for diverse organizational structures including large physician groups and independent practice associations.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.